Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
The anti-PA IgG1, IgG2, IgG3, and IgG4 subclass responses to clinical anthrax and to different numbers of anthrax vaccine adsorbed (AVA, BioThrax) injections were determined in a cross-sectional study of sera from 63 vaccinees and 13 clinical anthrax patients. The data show that both vaccination with three AVA injections and clinical anthrax elicit anti-PA IgG1, IgG2, and IgG3 subclass responses. An anti-PA IgG4 response was detected in AVA recipients after the fourth injection. The anthrax lethal toxin (LTx) neutralization efficacy of sera from recipients who received 4 to > or =10 AVA injections did not vary significantly in relation to changes in distribution of anti-PA IgG1 and IgG4 subclasses.
Semenova
V A
VA
Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. vsemenova@cdc.gov
Schmidt
D S
DS
Taylor
T H
TH
Li
H
H
Steward-Clark
E
E
Soroka
S D
SD
Ballard
M M
MM
Quinn
C P
CP
D000328:Adult; D000368:Aged; D000881:Anthrax / Q000276:immunology*; D022122:Anthrax Vaccines / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000097:blood* / Q000145:classification*; D000942:Antigens, Bacterial / Q000276:immunology*; D000992:Antitoxins / Q000097:blood; D001427:Bacterial Toxins / Q000276:immunology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000145:classification*; D008297:Male; D008875:Middle Aged
D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D000992:Antitoxins; D001427:Bacterial Toxins; D007074:Immunoglobulin G; C030325:anthrax toxin